Hillevax (HLVX) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Hillevax in October 2026.
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The Company has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Hillevax (HLVX) Stock Forecast
Analyst price target, next 12 months
$31.00
+1355.4% vs today's $2.13
Price range over the last 12 months
Close to its 12-month high
Analysts covering Hillevax have a consensus 12-month target of $31.00, above the current price of $2.13.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 18 Jul 2025.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Hillevax's stock, with a target price indicating significant potential growth.
Financial Health
Hillevax is generating strong cash flow and has a healthy book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.